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Abstract: The main functions of the abundant polypeptide toxins present in scorpion 
venoms are the debilitation of arthropod prey or defence against predators. These effects are 
achieved mainly through the blocking of an array of ion channel types within the membranes 
of excitable cells. However, while these ion channel-blocking toxins are tightly-folded by 
multiple disulphide bridges between cysteine residues, there are additional groups of 
peptides in the venoms that are devoid of cysteine residues. These non-disulphide bridged 
peptides are the subject of much research interest, and among these are peptides that exhibit 
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antimicrobial activity. Here, we describe two novel non-disulphide-bridged antimicrobial 
peptides that are present in the venom of the North African scorpion, Androctonus aeneas. 
The cDNAs encoding the biosynthetic precursors of both peptides were cloned from a 
venom-derived cDNA library using 3'- and 5'-RACE strategies. Both translated precursors 
contained open-reading frames of 74 amino acid residues, each encoding one copy of a 
putative novel nonadecapeptide, whose primary structures were FLFSLIPSVIAGLVSAIRN 
and FLFSLIPSAIAGLVSAIRN, respectively. Both peptides were C-terminally amidated. 
Synthetic versions of each natural peptide displayed broad-spectrum antimicrobial activities, 
but were devoid of antiproliferative activity against human cancer cell lines. However, 
synthetic analogues of each peptide, engineered for enhanced cationicity and amphipathicity, 
exhibited increases in antimicrobial potency and acquired antiproliferative activity  
against a range of human cancer cell lines. These data clearly illustrate the potential that  
natural peptide templates provide towards the design of synthetic analogues for  
therapeutic exploitation. 
Keywords: scorpion; venom; antimicrobial peptide; molecular cloning 
 
1. Introduction 
The vast majority of scorpion venom toxins studied thus far function through altering the functions 
of cell membrane ion channels [1–4]. Ion channels play fundamental roles in the regulation of many 
physiological aspects of all cells and, additionally, have been implicated in the pathogenesis of many 
diseases [5,6]. Thus, the acquisition of the ability to disturb the normal functions of these molecular 
targets supplies scorpions with a powerful mechanism of prey capture and, at the same time, a potent 
defensive weapon against competing conspecifics and predators [1–4]. Actually, which function came 
first in their evolutionary history is open to debate. 
The classification schemes for scorpion toxins are various and depend on the criteria that are used. 
They can be classified according to their molecular size (or, rather, their number of constituent amino 
acid residues) into long and short chain toxins or according to their mechanism of action into neurotoxic 
and cytotoxic toxins [1–4]. Another method used to classify scorpion toxins is based on the presence or 
absence of discrete structural features—disulphide bridges—and the two groups are thus those that have 
these and those that do not [7]. The ion channel-interacting toxins universally fall into the first group. 
In contrast to these, scorpion venom peptides without disulphide bridges constitute a minor fraction 
of the venom peptidome, and although only a few of these components have been isolated and 
biologically-characterised, nevertheless, they are diverse in both their structures and putative functions. 
Most of these peptide toxins are low molecular mass peptides of 13–50 amino acid residues and are 
either predominantly bradykinin-potentiating peptides (BPPs) or antimicrobial peptides (AMPs), while 
others may have protease inhibitory activity [7,8]. 
The AMPs from scorpion venom are usually cationic, amphipathic, α-helical peptides of low 
molecular mass (2–5 kD). They exhibit a broad-spectrum of activity against Gram-positive bacteria, 
Gram-negative bacteria and fungi, by causing membrane lysis. Some peptides, such as hadrurin, are 
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highly potent against both Gram-positive bacteria and Gram-negative bacteria without an apparent 
preference, whereas others exhibit more selective activity against either Gram-negative bacteria 
(parabutoporin) or Gram-positive bacteria (IsCT and BmKn2) [9,10]. 
Here, we report two novel peptides isolated from the venom of the North African scorpion, 
Androctonus aeneas, that were shown to have more selective growth-inhibitory activities against the 
Gram-positive bacterium, Staphylococcus aureus (S. aureas), and the yeast, Candida albicans  
(C. albicans), than against the Gram-negative bacterium, Escherichia coli (E. coli). The primary 
structures of these two novel AMPs, which were named AaeAP1 and AaeAP2, were established by 
MS/MS fragmentation sequencing using an electrospray ionisation (ESI) mass spectrometer.  
By isolating venom-derived polyadenylated mRNA, a cDNA library was constructed, and through the 
application of RACE PCR, the cDNAs encoding the biosynthetic precursors of both novel peptides were 
cloned. Both mature peptides, as predicted from the respective cDNA open-reading frames, were located 
in the same reverse-phase HPLC fraction of venom. Synthetic replicates of both natural AMPs were 
produced by solid-phase peptide synthesis, as were cationicity-, amphipathicity-enhanced analogues of 
each, named AaeAP1a and AaeAP2a, respectively. All four synthetic peptides were evaluated for 
antimicrobial, haemolytic and anticancer cell activities. The synthetic analogues, AaeAP1a and 
AaeAP2a, were, as expected, more potent in terms of their antimicrobial activities when compared to 
their corresponding templates, with only a small increase observed in haemolytic activity. In contrast, 
antiproliferative activity against a panel of human cancer lines was only observed for the analogue 
peptides and was absent for the natural templates. 
2. Results 
2.1. Identification and Structural Analysis of Mature Novel AMPs from Venom 
Screening of the reverse-phase HPLC fractions of lyophilised Androctonus aeneas venom for 
antimicrobial activity resulted in the identification of significant antimicrobial activity in a single 
fraction, number 145 (Figure 1). Analysis of the doubly-charged ions of the two major peptides present 
in this fraction by MS/MS, with subsequent sequence calling based on fragment ion profiles, revealed 
the presence of two novel, structurally-related putative antimicrobial peptides. As the more  
readily-fragmented doubly-charged ions from each peptide were used for MS/MS fragmentation,  
the resultant spectra contained both singly- and doubly-charged fragment ions (Tables 1 and 2). 
2.2. Cloning of AMP Precursor-Encoding cDNAs 
Two novel AMP-encoding cDNAs were consistently amplified and cloned from the cDNA library 
derived from the venom of the scorpion, Androctonus aeneas, and each encoded a single copy of their 
respective mature peptides (Figure 2). Translation of the open reading frames of these homologous AMP 
biosynthetic precursors demonstrated that each consisted of 74 amino acid residues and that the 
conserved prepro-region of each peptide precursor open-reading frame included a putative 22-amino 
acid residue signal peptide followed directly by the mature peptide sequences. The mature peptide 
sequences were flanked at their C-terminals by the post-translational α-amidation signal motif,  
-Gly-Arg-, indicating the high probability that each mature peptide sequence was C-terminally amidated. 
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The peptides were named AaeAP1 and AaeAP2, in accordance with the accepted terminology  
(Aae = Androctonus aeneas; AP = antimicrobial peptide). The alignment of both peptides with 
homologues in the NCBI database is shown in Table 3. The nucleotide sequences of the  
precursor-encoding cDNAs of both peptides have been deposited in the European Molecular Biology 
Laboratory Nucleotide Sequence Database under the accession codes, HG792997 (AaeAP1) and 
HG792998 (AaeAP2). 
 
(A) 
 
(B) 
Figure 1. (A) Reverse-phase HPLC chromatogram of lyophilised Androctonus aeneas 
venom. The arrow indicates the elution position/retention time of the peptide fraction (#145) 
exhibiting antimicrobial activity. AU = 214 nm, and the gradient was formed from 
TFA/water (0.05:99.95, v/v) to TFA/water/acetonitrile (0.1:19.95:80.00, v/v/v) in 240 min at 
a flow rate of 1 mL/min. (B) MALDI-TOF mass spectrum of a sample of Fraction #145 
indicating singly-charged [M + H]+ ions at m/z 1989.50 and m/z 2017.68. The ion at  
m/z 2039.07 is likely to be a sodium adduct ion [M + Na]+ of the peptide at m/z 2017.68. 
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Table 1. Predicted singly- and doubly-charged b-ions and y-ions arising from MS/MS 
fragmentation of AaeAP1. Ions observed following MS/MS fragmentation are indicated in 
bold typeface and are underlined. 
#1 b(1+) b(2+) Sequence y(1+) y(2+) #2 
1 148.07570 74.54149 F - - 19 
2 261.15977 131.08352 L 1869.13213 935.06970 18 
3 408.22819 204.61773 F 1756.04806 878.52767 17 
4 495.26022 248.13375 S 1608.97964 804.99346 16 
5 608.34429 304.67578 L 1521.94761 761.47744 15 
6 721.42836 361.21782 I 1408.86354 704.93541 14 
7 818.48113 409.74420 P 1295.77947 648.39337 13 
8 905.51316 453.26022 S 1198.72670 599.86699 12 
9 1004.58158 502.79443 V 1111.69467 556.35097 11 
10 1117.66565 559.33646 I 1012.62625 506.81676 10 
11 1188.70277 594.85502 A 899.54218 450.27473 9 
12 1245.72424 623.36576 G 828.50506 414.75617 8 
13 1358.80831 679.90779 L 771.48359 386.24543 7 
14 1457.87673 729.44200 V 658.39952 329.70340 6 
15 1544.90876 772.95802 S 559.33110 280.16919 5 
16 1615.94588 808.47658 A 472.29907 236.65317 4 
17 1729.02995 865.01861 I 401.26195 201.13461 3 
18 1885.13107 943.06917 R 288.17788 144.59258 2 
19 - - C-Amidated 132.07676 66.54202 1 
Table 2. Predicted singly- and doubly-charged b-ions and y-ions arising from MS/MS 
fragmentation of AaeAP2. Ions observed following MS/MS fragmentation are indicated in 
bold typeface and are underlined. 
#1 b(1+) b(2+) Sequence y(1+) y(2+) #2 
1 148.07570 74.54149 F - - 19 
2 261.15977 131.08352 L 1841.10083 921.05405 18 
3 408.22819 204.61773 F 1728.01676 864.51202 17 
4 495.26022 248.13375 S 1580.94834 790.97781 16 
5 608.34429 304.67578 L 1493.91631 747.46179 15 
6 721.42836 361.21782 I 1380.83224 690.91976 14 
7 818.48113 409.74420 P 1267.74817 634.37772 13 
8 905.51316 453.26022 S 1170.69540 585.85134 12 
9 976.55028 488.77878 A 1083.66337 542.33532 11 
10 1089.63435 545.32081 I 1012.62625 506.81676 10 
11 1160.67147 580.83937 A 899.54218 450.27473 9 
12 1217.69294 609.35011 G 828.50506 414.75617 8 
13 1330.77701 665.89214 L 771.48359 386.24543 7 
14 1429.84543 715.42635 V 658.39952 329.70340 6 
15 1516.87746 758.94237 S 559.33110 280.16919 5 
16 1587.91458 794.46093 A 472.29907 236.65317 4 
17 1700.99865 851.00296 I 401.26195 201.13461 3 
18 1857.09977 929.05352 R 288.17788 144.59258 2 
19 - - C-Amidated 132.07676 66.54202 1 
Toxins 2015, 7 224 
 
 
 
Figure 2. Nucleotide and translated open-reading frame amino acid sequences of cloned 
cDNAs encoding the biosynthetic precursors of AaeAP1 (A) and AaeAP2 (B). Putative 
signal peptides are double-underlined; mature peptides are single-underlined; and stop 
codons are indicated by asterisks. 
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2.3. Secondary Structure Prediction and Physiochemical Properties of AaeAP1 and -2 and  
Their Cationicity-/Amphipathicity-Enhanced Analogues, AaeAP1a and -2a 
The data obtained through the application of robust web-based programmes for secondary structure 
prediction and assessment of the additional physicochemical properties of both synthetic replicates of 
the natural peptides and their engineered cationicity-enhanced analogues are summarised in Table 4, and 
helical wheel plots are illustrated in Figure 3, respectively. 
  
AaeAP1 FLFSLIPSVIAGLVSAIRN AaeAP2 FLFSLIPSAIAGLVSAIRN 
  
AaeAP1a FLFKLIPKVIKGLVKAIRK AaeAP2a FLFKLIPKAIKGLVKAIRK 
Figure 3. Helical wheel plots of AaeAP1, AaeAP2, AaeAP1a and AaeAP2a. Note the 
increased amphipathicity and cationicity that have been engineered into the analogues, 
AaeAP1a and AaeAP2a. 
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Table 3. Alignment of the primary structures of the novel antimicrobial peptides, AaeAP1 and AaeAP2, with scorpion venom homologues 
present in the NCBI database. Note that AaeAP1 and AaeAP2 are both nonadecapeptides, and the majority of homologues are octadecapeptides. 
Note also that all peptides are C-terminally amidated (a). Identical residues are represented by dashes. 
Species Peptide Primary structure Nucleotide sequence database 
Androctonus aeneas AaeAP1 FLFSLIPSVIAGLVSAIRNa (Accession No. HG792997) 
Androctonus aeneas AaeAP2 --------A----------a (Accession No. HG792998) 
Mesobuthus martensii Kb1 --------A-S--I--FKa (Accession No. AF159979) 
Mesobuthus eupeus caerin-like AMP --------A-S--I--FKa (Accession No. KC108907) 
Androctonus amoreuxi AamAP1 -------HA-G--I--FKa (Accession No. FR821613) 
Isometrus maculatus imcroporin -F---L--L-G------Ka (Accession No. FJ750949) 
Lychas mucronatus mucroporin  --G----L-G-----FKa (Accession No. EU669864) 
Mesobuthus martensii BmKb2 --S-----A-S--I--FKa (Accession No. AF543048) 
Tityus costatus AMP clone 5 -F------L-G---F--Ka (Accession No. AY740687) 
Androctonus amoreuxi AamAP2 -P-----HA-GG-ISAIKa (Accession No. FR821614) 
Table 4. Secondary structure predictions and some physiochemical properties of AaeAPs and their cationicity-enhanced analogues described in 
this study. Net charges were calculated at pH 7. The random coil is represented by c, the extended strand by e and the “helix” by h. 
Peptides Secondary structure α-Helix (%) Hydrophobicity (H) Hydrophobic moment (μH) Net charge 
AaeAP1 
FLFSLIPSVIAGLVSAIRN  
cccccccchhhheeeeeec 
21.05 0.849 0.455 +2 
AaeAP2 
FLFSLIPSAIAGLVSAIRN  
cccccccchhhheeeeeec 
21.05 0.801 0.428 +2 
AaeAP1a 
FLFKLIPKAIKGLVKAIRK  
ccceecchhhhhheeeeec 
31.58 0.610 0.669 +7 
AaeAP2a 
FLFKLIPKVIKGLVKAIRK  
ccceecchhhhhheeeeec 
31.58 0.562 0.641 +7 
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2.4. Antimicrobial/Haemolytic Activities of AaeAP1 and -2 and Their  
Cationicity-/Amphipathicity-Enhanced Analogues, AaeAP1a and -2a 
The data obtained from both MIC and MBC assays of the four synthetic peptides (natural and 
analogues) are summarised in Tables 5 and 6. AaeAP1 and AaeAP2 displayed identical MICs against  
S. aureus (16 mg/L) and C. albicans (32 mg/L), respectively, but both were ineffective against E. coli 
up to and including the highest concentrations tested (512 mg/L). Their MBCs were found to be generally 
double that of their MICs at 32 mg/L for S. aureus with AaeAP1 and 64 mg/L for C. albicans with both 
synthetic natural peptides. However, the MBC for AaeAP2 against S. aureus remained the same as its 
MIC. AaeAP2 was found to be four-fold less haemolytic than AaeAP1, requiring 64 mg/L rather than 
16 mg/L to effectively completely lyse the red blood cells employed in the model assay. The biological 
behaviour of the two synthetic analogues was found to be quite different to that of the synthetic natural 
peptides. The MICs of both analogues were both found to be four-fold lower against S. aureus (4 mg/L) 
and eight-fold lower against C. albicans (4 mg/L). The most dramatic observation, however, was that 
both analogues exhibited a potent action against E. coli with identical MICs of 16 mg/L. The haemolytic 
activity of AaeAP1 was reduced two-fold by cationicity/amphipathicity enhancement to 32 mg/L,  
but that of AaeAP2 remained unchanged at 64 mg/L. 
Table 5. Minimum inhibitory concentrations (MICs) and minimum bactericidal 
concentrations (MBCs) of synthetic AaeAP1 and AaeAP2 and their cationicity/amphipathicity 
analogues, AaeAP1a and AaeAP2a; NT, not tested.  
Peptides 
MIC (mg/L) MBC (mg/L) 100% hemolysis (mg/L) 
S. aureus E. coli C. albicans S. aureus E. coli C. albicans  Horse red cells 
AaeAP1 16 >512 32 32 NT 64 16 
AaeAP2 16 >512 32 16 NT 64 64 
AaeAP1a 4 16 4 32 32 16 32 
AaeAP2a 4 16 4 32 32 16 64 
Table 6. Structures of natural peptides and their cationicity-/amphipathicity-enhanced analogues. 
Peptide Primary structure Mass (Da)  
AaeAP1 FLFSLIPSVIAGLVSAIRNamide 2016.18 
AaeAP2 FLFSLIPSAIAGLVSAIRNamide 1986.15 
AaeAP1a FLFKLIPKVIKGLVKAIRKamide 2209.48 
AaeAP2a FLFKLIPKAIKGLVKAIRKamide 2181.45 
      *   *  *   *   *  
* Sites of cationicity enhancement using lysyl (K) residue substitution for Ser(S)4, Ser(S)8, Ala(A)11 Ser(S)15 
and Asn(N)19. Net positive charge increase from +2 (natural peptides) to +7 (respective analogues). 
2.5. The Antiproliferative Effects of AaeAP1 and -2 and Their Cationicity-/Amphipathicity-Enhanced 
Analogues, AaeAP1a and -2a, against a Panel of Human Cancer Cell Lines 
The ability of the four peptides to inhibit the proliferation of four different human cancer cell lines, 
at concentrations ranging between 10−4 and 10−9 M, was assessed using the MTT assay. The synthetic 
replicates of the natural peptides exhibited no activity on the proliferation of all of the human cancer cell 
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lines tested at the concentrations employed. In contrast, both synthetic cationic-/amphipathicity-enhanced 
analogues displayed antiproliferative activity against all four cell lines (Figure 4). 
  
  
  
Figure 4. Cont. 
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Figure 4. Dose-dependent antiproliferative effects of the analogues, AaeAP1a and 
AaeAP2a, on the human cancer cell lines, H460, MB435s, MCF-7 and PC3, after 24 h of 
incubation. The levels of significance are: * p < 0.05; ** p < 0.01; *** p < 0.001. Note that 
at low concentrations (10−9 M and 10−8 M), AaeAP1a significantly increased the proliferation 
of H460 cancer cells (p < 0.01). AaeAP2a significantly increased (p < 0.05) the proliferation 
of MB435s cancer cells at 10−9 M and the proliferation of MCF-7 cancer cells at 10−8 M  
(p < 0.05) and at 10−9 M (p < 0.01). The growth inhibition of cells at each peptide 
concentration was calculated as a percentage of the growth observed in controls, which was 
treated as 100%. 
3. Discussion 
The earliest scorpion fossils date back to the Silurian Period some 430 million years ago, and these 
possess the typical telson that, in modern scorpions, is the organ that synthesises, stores and delivers 
venom [11]. Scorpion venoms have thus been subjected to aeons of natural selection, resulting in 
optimisation of the component toxins for molecular targets within their predominantly insect prey to 
facilitate rapid and effective immobilisation prior to ingestion [2,3,12,13]. This prerequisite rapid mode 
of action has resulted in the evolution of an array of neuromuscular toxins that target many types of ion 
channels in the membranes of excitable cells [2,3]. 
Although primarily directed against molecular targets in insect prey, some of the component 
neurotoxins are also effective on predators and can be used defensively. Ion channel proteins are 
functionally fundamental to the normal physiology of all cells, and often, sites of toxin action on specific 
molecular targets are conserved across diverse and distant taxa, such that a small number of scorpions 
possess venoms that are toxic to humans [14,15]. However, of the approximately 1,700 species of 
scorpions, only around 30 species have venoms that are considered to be so [2]. Nevertheless, this small 
number of species is of widespread global distribution and causes significant human morbidity and 
mortality, which is one of the major reasons why scorpion venom research is so important [2–4,16].  
In view of the fact that scorpion envenomation can be lethal, even within developed countries, such as 
the U.S., the major focus of research on scorpion venom has been on the lethal components: the ion 
channel toxins [15–18]. Two additional peptides, DLDGQIDRFRNFR and DAELEELLSKLPIY, 
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falling between the -KR-processing sites and/or the C-terminus within both precursors, were not detected 
in the reverse-phase HPLC fractions of venom, but were synthesized and subjected to the bioassays 
described here, in which they were found to be inactive (data not shown). 
However, scorpion venom contains a significant number of peptides that do not act on ion channels 
and whose precise biological actions remain obscure. One of these groups are the so-called antimicrobial 
peptides [19], and little attention was paid to these until the isolation of the prototypes, hadrurin  
and scorpine, from the venoms of the scorpions, Hadrurus aztecus and Pandinus imperator,  
respectively [20,21]. Since then, several other AMPs with a broad spectrum of action have been isolated 
from the venoms of other scorpions [22,23]. Since some scorpions had been observed to spray venom 
on their own bodies to clean invading microorganisms, these venom AMPs were assumed as defence 
tools against infection [7,20,21]. This hypothesis was further supported by the observation of the 
upregulation of transcription of AMPs within the bacterially-challenged venom glands of the scorpion, 
Buthus martensii [24]. However, in common with many other arthropod taxa, scorpions possess classical 
potent broad-spectrum defensins in their haemolymph, and the production of these from haemocytes is 
induced upon infection [25]. These defensins are ancient molecules, as evidenced by the finding of 
highly-conserved structural homologues in ticks, mussels and even fungi [26]. 
The present study describes the molecular cloning of two putative AMP-encoding cDNAs from a 
venom-derived cDNA library of the scorpion, Androctonus aeneas, with subsequent identification of the 
mature AMPs in venom fractions, their chemical synthesis and determination of their antimicrobial 
spectra and potencies. The AMPs were both C-terminally-amidated 19-mers and exhibited moderately 
potent activity against a standard Gram-positive bacterium and a yeast, but were ineffective against a 
standard Gram-negative bacterium. C-terminal amidation is a common feature of bioactive peptides 
found in many taxa across the evolutionary tree and is thought to act in eliminating the usual C-terminal 
negative charge, thus creating a more hydrophobic character in this region that facilitates peptide 
interaction, either specifically or non-specifically with their membrane target [27]. As endogenous 
scorpion defensins are much more potent and to have a broad spectrum in their actions, these  
venom-derived AMPs may not function primarily as anti-infective agents, but may have another primary 
biological role. Nevertheless, due to their low molecular masses and ease of chemical synthesis, they 
provide the medicinal chemist with natural templates for the design of analogues with the view of 
potentially improving both their potencies and spectra of action through rational structural engineering. 
As a result of many studies on the mode of action of AMPs, it has become clear that a few fundamental 
physicochemical features, namely the degree of cationicity and amphipathicity, are known to be 
important for functionality. For this reason, we engineered analogues of each AMP with enhanced 
cationic and amphipathic features. To this end, helical wheel plots were constructed for each natural 
AMP template to determine the distribution of individual amino acid residue chains; then, several were 
substituted by Lys (K) residues, and the plots were reconstructed. The two analogues so designed had 
clear and unambiguous amphipathicity, as shown in these latter plots, and there was an associated 
significant increase in their overall net positive charges. Of course, such plots are predictive, and the 
resulting engineered peptides were then subjected to a bioassay to determine if such modifications had 
produced any changes in the biological activities. 
As expected, the MICs of both analogue peptides against S. aureus and C. albicans decreased  
four-fold (16 > 4 mg/L) and eight-fold (32 > 4 mg/L), respectively. However, both analogues were found 
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to possess a potent activity against E. coli (16 mg/L), an activity that was not noted with the synthetic 
natural peptide templates at concentrations up to and including 512 mg/L. The MBC observed for both 
synthetic natural peptides against S. aureus remained essentially unchanged for the analogues, but 
decreased four-fold against C. albicans (64 > 16 mg/L). The MBC for E. coli obtained with both 
analogues was found to be 32 mg/L. Despite these observed increases in antimicrobial potencies and the 
broadening of the spectrum of actions, the analogue peptides either remained unchanged in haemolytic 
potential (AaeAP2a, 64 mg/L) or exhibited a reduction in such a potential (AaeAP1a, 16 > 32 mg/L). 
These cytotoxic indices remained above their respective MIC values, particularly for S aureus and  
C. albicans. Thus, the engineering of these cationicity- and amphipathicity-enhanced analogues from 
both natural peptide templates resulted in clear increases in both their antimicrobial potencies and 
spectrum of activity, while leaving their potential for mammalian cell cytotoxicity relatively unchanged 
or slightly reduced. 
Several previous studies on antimicrobial peptides from a variety of natural sources have reported 
that some possess antiproliferative activity on human cancer cell lines [28]. This effect undoubtedly 
increases the putative therapeutic potential of such peptides and could provide a novel means of treating 
human cancers [28]. The synthetic natural peptides, AaeAP1 and AaeAP2, described here, were found 
to be inactive for inhibiting the proliferation of four different human cancer cell lines. However,  
their respective cationicity- and amphipathicity-enhanced analogues were both found to possess a  
dose-dependent inhibition of all four cell lines. The engineered increase in net positive charge in both 
analogues probably facilitated a greater interaction with target cell membranes. This effect is clearly 
observed by the increased potency in the antimicrobial effects and appears with both analogues for 
cancer cells. It could be that the optimum micellar concentration for cancer cell membrane perturbation 
is exceeded for the analogues, but sub-optimal for the natural peptides. This is an observation that 
deserves further study. At a concentration of 10−5 M (equivalent to approximately 22 mg/L),  
both peptides caused more than 85% inhibition of the proliferation of cells. However, their effects were 
somewhat more selective on certain cell lines at much lower concentrations, indicating that a general 
cytotoxic effect was not responsible for all of the observed effects. For instance, a significant inhibition 
of the proliferation of the human prostate cancer cell line, PC3 (p < 0.001 compared to the controls), was 
observed at a concentration of 10−9 M (1 nM–2.2 µg/L), at which concentration there was no observable 
haemolytic effects. Of additional interest were the observations with the other three cell lines at these 
sub-micromolar concentrations, where a significant enhancement of proliferation, ranging from p-values 
of <0.05 through 0.001, was observed for both analogues. Antimicrobial peptides are thought to act 
predominantly through membrane lysis of both microbial and cancer cells, due to their similarities in 
membrane compositions, which are different from those of normal eukaryotic cells [26,28]. However, 
there is recent evidence to suggest that other, more subtle mechanisms may be involved, which include 
effects on multiple intracellular targets [28–30]. This could be at concentrations lower than those that 
cause cytolysis, and increasing membrane permeability at sub-lytic concentrations affords an increase 
in proliferative potential, due to some means as simple as increasing access to nutrients or growth factors 
in the culture medium or by some other more complex route, such as a positive modulation of discrete 
signalling pathways.  
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4. Experimental Section 
4.1. Acquisition of Scorpion Venom 
A 10-mg sample of authentic lyophilised Androctonus aeneas venom was obtained from Latoxan, 
Valence, France. Donor scorpions were collected in the field and identified by experts before relocation 
to the company facility in France. Venom was collected by trained individuals using electrical 
stimulation (15 V) consistent with obtaining sufficient material, but also with causing a low degree of 
damage to the animals. Venom samples were obtained by this procedure at regular intervals for 
considerable periods of time (Latoxan, personal communication). All procedures using live animals had 
been approved by appropriate national licensing and ethics authorities, and permits to acquire animals 
from the wild had been secured from appropriate national bodies prior to the collection and relocation 
of specimens. 
4.2. Isolation and Structural Characterisation of Antimicrobial Activity from Lyophilised Venom 
A 5-mg sample of lyophilised Androctonus aeneas venom was dissolved in 0.5 mL of trifluoroacetic 
acid (TFA)/water (0.05/99.95; v/v) and clarified by centrifugation (1100× g; 5 min). The supernatant 
was decanted and subjected to reverse-phase HPLC fractionation using a Waters HPLC system 
(Worcester County, MA, USA) fitted with an analytical column (Phenomenex C-5; 250 mm × 4.6 mm). 
This was eluted with a linear gradient formed from TFA/water (0.05/99.95; v/v) to 
TFA/water/acetonitrile (0.05/19.95/80.00; v/v/v) in 240 min at a flow rate of 1 mL/min. The column 
effluent was continuously monitored at λ 214 nm, and fractions (1 mL) were automatically collected at 
minute intervals. Samples (100 μL) were removed from each fraction, lyophilised and stored at −20 °C 
prior to being subjected to the antimicrobial assay. The molecular masses of the peptides in each fraction 
displaying antimicrobial activity were analysed using matrix-assisted, laser desorption/ionisation,  
time-of-flight mass spectrometry (MALDI-TOF MS) on a linear time-of-flight Voyager DE mass 
spectrometer (Perseptive Biosystems, Framingham, MA, USA) in positive detection mode, using  
α-cyano-4-hydroxycinnamic acid as the matrix. The amino acid sequences of the resolved peptides in 
the active antimicrobial fraction were determined by MS/MS fragmentation sequencing using an  
LCQ-Fleet electrospray, ion-trap mass spectrometer (Thermo Fisher Scientific, San Jose, CA, USA). 
4.3. Antimicrobial Screening Assays 
The standard panel of microorganisms used for activity screening were the Gram-positive bacterium, 
Staphylococcus aureus (S. aureus) (NCTC 10788), the Gram-negative bacterium, Escherichia coli  
(E. coli) (NCTC 10418), and the yeast, Candida albicans (C. aibican) (NCPF 1467). All are used 
routinely for such purposes and are non-pathogenic strains. The antimicrobial activity of fraction 
samples was initially evaluated using a simple inhibition zone assay on Luria–Bertani (LB)-agarose 
plates [31]. To study the microbicidal effects, each fraction sample, following lyophilisation and 
reconstitution in phosphate-buffered saline (PBS), was added to a 2 mm-diameter hole punched in the 
surface of the agar plate. The plates were then incubated at 37 °C overnight.  
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4.4. Molecular Cloning of Antimicrobial Peptide Biosynthetic Precursor-Encoding cDNAs from the 
Venom-Derived cDNA Library 
A 5-mg sample of lyophilised venom was dissolved in 1 mL of cell lysis/mRNA protection buffer 
supplied by Dynal Biotech, Merseyside, UK, and polyadenylated mRNA was isolated by magnetic  
oligo-dT beads, as described by the manufacturer (Dynal Biotech). The isolated mRNA was subjected 
to 5'- and 3'-rapid amplification of cDNA ends (RACE) procedures to obtain full-length antimicrobial 
peptide precursor nucleic acid sequence data using a SMART-RACE kit (Clontech, Oxford, UK), 
essentially as described by the manufacturer. Briefly, the 3'-RACE reactions employed a nested universal 
primer (NUP) (supplied with the kit) and a degenerate sense primer pool (S1: 5'-TTYHTITTYW 
SNHTIHTICC-3') (Y = C/T, H = A/T/C, I = deoxyinosine, W = A/T, S = C/G, N = A/C/T/G) that was 
complementary to the amino acid sequence, F-L/I-F-S-L/I-L/I-P-, of the N-terminal region of the 
scorpion venom AMPs. The 3'-RACE reactions were purified and cloned using a pGEM-T vector system 
(Promega Corporation, Southampton, UK) and sequenced using an ABI 3100 automated sequencer. The 
sequence data obtained from these 3'-RACE products were used to design a specific antisense primer 
(AS: 5'-CGAAACGAGGAAGAGAGACCAA-3') to a conserved site within the 3'-non-translated region 
of these cDNAs. 5'-RACE was carried out using this specific primer in conjunction with the NUP RACE 
primer, and the resultant products were purified, cloned and sequenced. 
4.5. Prediction of Putative AMP Secondary Structures and Physicochemical Properties 
Putative peptide secondary structures were predicted using the GOR secondary structure  
prediction method software (Version 2.2.26, Pole Bioinformatique Lyonnais, Lyon, France, 2014)  
(http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_gor4.html). Additional physicochemical 
properties, including hydrophobicity, hydrophobic moments, net charge at neutral pH and helical wheel 
plots, were determined by using the Heliquest server on-line (http://heliquest.ipmc.cnrs.fr/cgi-bin/ 
ComputParamsV2.py) [32]. 
4.6. Peptide Synthesis and Purification 
The two natural antimicrobial peptides and their cationicity-/amphipathicity-enhanced analogues  
were each separately synthesised by a solid-phase methodology using Rink amide resin and standard 
Fmoc chemistry, by means of an automated PS3 peptide synthesiser (Protein Technologies, Tucson, AZ, 
USA), followed by deprotection and cleavage from the resin. Each synthetic peptide was analysed by 
both reverse-phase HPLC and MALDI-TOF mass spectrometry to establish the degree of purity  
and authenticity.  
4.7. Antimicrobial Minimal Inhibitory Concentration and Minimum Bactericidal Assays 
The antimicrobial activity of each synthetic peptide was assessed by means of determining the 
minimal inhibitory concentrations (MICs) against model strains of Gram-positive bacteria, S. aureus,  
Gram-negative bacteria, E. coli, and yeast, C. albicans, respectively. The model microorganisms were 
initially incubated in Mueller–Hinton broth (MHB) for 16–20 h. Upon achieving their respective 
logarithmic growth phases, as measured by the optical density (OD) of media at 550 nm, the cultures 
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were diluted to 1 × 106 colony-forming units (cfu)/mL for the bacteria and to 5 × 105 cfu/mL for the 
yeast. Samples of these were then added to 96-well microtitre plates and mixed with the tested peptides 
at various concentrations (1–512 mg/L). After 24 h of incubation, the OD of each well was measured at 
550 nm using a Synergy HT plate reader (BioTek, Winooski, VT, USA), and the data were analysed 
using GraphPad Prism 5 software. The MIC was defined as the minimum concentration of peptide with 
an OD the same as the negative control (medium minus microorganisms). After this, 10 μL of the 
medium from each well were inoculated onto a Mueller–Hinton agar (MHA) plate and incubated for  
24 h for the measurement of minimum bactericidal concentrations (MBCs), which were defined as the 
concentrations of peptide from which no colonies could be grown. 
4.8. Haemolysis Assay 
A 2% (v/v) suspension of red blood cells was prepared from defibrinated horse blood  
(TCS Biosciences Ltd., Buckingham, UK). Peptide solutions at different concentrations (1–512 mg/L) 
were prepared as described in the previous section. Red blood cell suspension samples (200 μL) were 
incubated with the range of peptide concentrations as defined before, at 37 °C for 60 min and 120 min. 
Lysis of red cells was assessed by measurement of optical density at λ = 550 nm using an ELISA plate 
reader (Biolise BioTek EL808, Winooski, VT, USA). The negative controls employed consisted of a 2% 
(v/v) red cell suspension and sodium phosphate-buffered saline (PBS) in equal volumes, and the positive 
controls consisted of a 2% (v/v) red cell suspension and an equal volume of PBS containing 2% (v/v) of 
the non-ionic detergent, Triton X-100 (Sigma-Aldrich, St. Louis, MO, USA). 
4.9. Culture and Maintenance of Human Cancer Cell Lines 
The human prostate carcinoma cell line, PC-3, and the human lung adenocarcinoma cell line,  
NCI-H460, were cultured using RPMI-1640 culture medium (Invitrogen, Paisley, UK). Before culturing 
the cells, this medium was supplemented with 10% (v/v) foetal bovine serum (FBS) (Sigma-Aldrich,  
St. Louis, MO, USA) and 0.1% (w/v) gentamicin (Sigma-Aldrich, St. Louis, MO, USA), and the cells 
were seeded into 150-cm2 culture flasks (Nunc, Roskilde, Denmark). The human breast carcinoma cell 
line, MDA-MB-435s, and the non-tumourigenic mammary gland cell line, MCF-7, were cultured using 
a Dulbecco’s modified eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO, USA), which was 
supplemented with 10% FBS and 0.1% gentamicin. The cells were seeded into 150-cm2 culture flasks. 
4.10. Assessment of Anti-Proliferative Effects of AMPs on Human Cancer Cells Using the MTT Cell 
Viability Assay 
Yellow-coloured MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) is reduced by 
the mitochondria of living cells to form a purple-coloured (formazan) crystalline derivative. These 
crystals can be solubilised by the addition of dimethyl sulphoxide (DMSO) (Sigma-Aldrich, St. Louis, 
MO, USA) and their concentration determined spectrophotometrically, as detailed below. 
The protocol employed has been described in detail previously [33]. Briefly, each cell line was  
seeded at a density of 5 × 103 cells per well onto 96-well plates. After this, cells were treated with various 
concentrations of peptides (10−9–10−4 M) or with serum-free medium alone (n = 8 for each) and were 
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incubated for 24 h. Following this, 10 μL of a 5-mg/mL MTT solution was added to each well and the 
plates incubated again for 4 h. The growth medium was later removed using a 1-mL syringe fitted with 
a 21-guage needle, and 100 μL of DMSO were added to each well and mixed vigorously to dissolve the 
formazan crystals that had developed. The absorbance was measured using an ELx808™ Absorbance 
Microplate Reader (BioTek, Winooski, VT, USA) at 550 nm, and the statistical analyses were performed 
using the Student’s t-test through GraphPad Prism software for Windows. The results were considered 
to be statistically significant if the p-value was <0.05. Growth inhibition of cells at each peptide 
concentration was calculated as the percentage of the growth observed in controls, which was treated  
as 100%. 
5. Conclusions 
Two novel 19-mer antimicrobial peptides were identified in the venom of the North African scorpion, 
Androctonus aeneas. Synthetic replicates of the novel natural peptides displayed antimicrobial activity 
against the Gram-positive bacterium, S. aureus, and the yeast, C. albicans, but were ineffective against 
the Gram-negative bacterium, E. coli, and at inhibiting the proliferation of four human cancer cell lines. 
In contrast, analogues of each, engineered for enhanced cationicity and amphipathicity, exhibited higher 
potencies against S. aureus and C. albicans and exhibited a high potency against E. coli. In addition, 
both analogues were effective at inhibiting the proliferation of all four human cancer cell lines with 
micromolar potencies and some with nanomolar potencies. These data illustrate the potential for the 
rational design of effective antimicrobial and anticancer peptides from natural peptide templates. 
Although preliminary in nature, the data presented the effective and selective actions of such designed 
peptide analogues on human cancer cells, and this is an area that warrants further and more  
systematic study. 
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